Press release

Globalpharma, a wholly owned subsidiary of Dubai Investments (DIC), signed seven strategic Memorandums of Understanding (MoUs) on May 21, 2026, to enhance its research and development, manufacturing, and sustainability capabilities.
Key partnerships include collaborations with ZIM Laboratories and Molkem Chemicals for product development, and Masibus and Rockwell Automation for implementing advanced manufacturing automation and digital technologies.
Financial and market expansion support will be provided through agreements with Emirates Development Bank (EDB) for structured financing and the Emirates Drug Establishment (EDE) for regulatory alignment and medicine security.
A sustainability initiative with 386 Sky Solar involves the installation of a 612 kWp rooftop solar plant at the Dubai Investment Park facility, projected to generate 25.3 GWh of clean energy and reduce 11,400 tonnes of CO2 emissions.